Antibodies have proven to be exquisite investigation tools in the field of life sciences. They also constitute one of the oldest and most successful biological products for diagnostics and therapeutics. This review investigates the current use of antibodies in target discovery. To address this topic in a larger context, established and emerging technologies that are expected to contribute to target discovery will first be examined. These technologies include: mass spectroscopic analysis of proteins, protein-protein interaction and other network analysis approaches, as well as protein and antibody arrays. The potential of antibody engineering and the ANTIBIOMIX technology will then be discussed; antibody therapeutics, however, will not be examined.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Molecular Basis for Short-Chain Thioester Hydrolysis by Acyl Hydrolases in -Acyltransferase Polyketide Synthases.
JACS Au
January 2025
Department of Chemistry, University of Warwick, Coventry CV4 7AL, U.K.
Polyketide synthases (PKSs) are multidomain enzymatic assembly lines that biosynthesize a wide selection of bioactive natural products from simple building blocks. In contrast to their -acyltransferase (AT) counterparts, -AT PKSs rely on stand-alone ATs to load extender units onto acyl carrier protein (ACP) domains embedded in the core PKS machinery. -AT PKS gene clusters also encode stand-alone acyl hydrolases (AHs), which are predicted to share the overall fold of ATs but function like type II thioesterases (TEs), hydrolyzing aberrant acyl chains from ACP domains to promote biosynthetic efficiency.
View Article and Find Full Text PDFAI-driven multi-omics integration for multi-scale predictive modeling of genotype-environment-phenotype relationships.
Comput Struct Biotechnol J
January 2025
Ph.D. Program in Computer Science, The Graduate Center, The City University of New York, New York, NY, USA.
Despite the wealth of single-cell multi-omics data, it remains challenging to predict the consequences of novel genetic and chemical perturbations in the human body. It requires knowledge of molecular interactions at all biological levels, encompassing disease models and humans. Current machine learning methods primarily establish statistical correlations between genotypes and phenotypes but struggle to identify physiologically significant causal factors, limiting their predictive power.
View Article and Find Full Text PDFBiocompatible covalent reactive groups (CRGs) play pivotal roles in several areas of chemical biology and the life sciences, including targeted covalent inhibitor design and preparation of advanced biologic drugs, such as antibody-drug conjugates. In this study, we present the discovery that the small, chlorinated polyketide natural product cyclohelminthiol II (CHM-II) acts as a new type of cysteine/thiol-targeting CRG incorporating both reversible and irreversible reactivity. We devise the first syntheses of four simple cyclohelminthols, (±)-cyclohelminthol I-IV, with selective chlorinations (at C and C) and a Ni-catalyzed reductive cross coupling between an enone, a vinyl bromide and triethylsilyl chloride as the key steps.
View Article and Find Full Text PDFInvestigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches.
Expert Opin Drug Discov
January 2025
Geriatric Neuropsychiatry Division, The Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Introduction: A substantial number of patients exhibit treatment-resistant depression (TRD), posing significant challenges to clinicians. The discovery of novel molecules or mechanisms that may underlie TRD pathogenesis and antidepressant actions are highly needed.
Areas Covered: Using the PubMed database, the authors searched for emerging evidence of novel approaches for TRD based on experimental and human studies.
Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer's disease.
Neural Regen Res
January 2025
Department of Dermatology, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China.
Alzheimer's disease, a devastating neurodegenerative disorder, is characterized by progressive cognitive decline, primarily due to amyloid-beta protein deposition and tau protein phosphorylation. Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the progression of Alzheimer's disease. Conventional drugs, such as donepezil, can only alleviate symptoms and are not able to prevent the underlying pathological processes or cognitive decline.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!